Therapeutic Area | MeSH |
---|---|
hemic and lymphatic diseases | D006425 |
nutritional and metabolic diseases | D009750 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MONOFERRIC | Pharmacosmos | N-208171 RX | 2020-01-16 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
monoferric | New Drug Application | 2024-09-04 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
iron-deficiency anemia | — | D018798 | D50 |
Code | Description |
---|---|
J1437 | Injection, ferric derisomaltose, 10 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anemia | D000740 | EFO_0004272 | D64.9 | — | — | 7 | 4 | — | 11 |
Iron deficiencies | D000090463 | — | E61.1 | — | — | 8 | 3 | — | 11 |
Iron-deficiency anemia | D018798 | — | D50 | — | — | 7 | 3 | — | 10 |
Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | 2 | — | 3 |
Left ventricular dysfunction | D018487 | — | — | — | — | — | 1 | — | 1 |
Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | 1 | — | 1 |
Spinal dysraphism | D016135 | EFO_1001210 | Q05 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Deficiency diseases | D003677 | EFO_1001067 | E63 | — | — | 5 | — | — | 5 |
Hypophosphatemia | D017674 | HP_0002148 | — | — | — | 2 | — | — | 2 |
Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | — | 1 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
Female genital neoplasms | D005833 | — | — | — | — | 1 | — | — | 1 |
Drug common name | Ferric derisomaltose |
INN | ferric derisomaltose |
Description | Ferric derisomaltose (FDI), sold under the brand name Monoferric among others, is a medication for the treatment of iron deficiency anemia (IDA) in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD). It was approved for use in the United States in January 2020. It is given intravenously.
|
Classification | Oligosaccharide |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1345510-43-1 |
RxCUI | — |
ChEMBL ID | CHEMBL4298187 |
ChEBI ID | — |
PubChem CID | 86278348 |
DrugBank | DB15617 |
UNII ID | AHU547PI9H (ChemIDplus, GSRS) |